Biocon subsidiary gets USFDA nod for generic drug for chronic heart failure

Q: How long will it take to read this news story?

The story "Biocon subsidiary gets USFDA nod for generic drug for chronic heart failure" has 163 words across 7 sentences, which will take approximately 1 - 2 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Biocon subsidiary gets USFDA nod for generic drug for chronic heart failure" was covered 4 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 152 news stories per day. It's most recent story was published 4 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22321356</li><li>URL: https://beamstart.com/news/biocon-subsidiary-gets-usfda-nod-17252106186235</li></ul>

Business Standard Logo Business Standard 4h ago

Biocon subsidiary gets USFDA nod for generic drug for chronic heart failure - Business Standard

Quick Summary:

Biotechnology firm Biocon said its subsidiary has received approval from the US health regulator to market a generic medication to treat chronic heart failure.

Biocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the US Food and Drug Administration (USFDA), the company said in a regulatory filing.

Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation.